Ligand Pharmaceuticals (NASDAQ:LGND) Issues Earnings Results

Ligand Pharmaceuticals (NASDAQ:LGND) announced its quarterly earnings results on Thursday. The biotechnology company reported $2.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.97 by $0.40, FiscalAI reports. Ligand Pharmaceuticals had a return on equity of 20.06% and a net margin of 67.88%.The company had revenue of $63.69 million during the quarter, compared to analyst estimates of $61.30 million. During the same quarter in the previous year, the firm posted $1.60 EPS. The firm’s quarterly revenue was up 33.8% on a year-over-year basis. Ligand Pharmaceuticals updated its FY 2026 guidance to 9.000-9.500 EPS.

Here are the key takeaways from Ligand Pharmaceuticals’ conference call:

• Second-quarter results exceeded growth expectations, with total revenue up 34% year over year to $64 million, royalty revenue up 32% to $48 million, and adjusted diluted EPS up 48% to $2.37.
• The recently closed XOMA Royalty acquisition adds more than 120 assets, including seven commercial programs and approximately 14 late-stage clinical programs, and is expected to contribute about $0.50 of adjusted EPS in the second half of 2026 and $1.50 in 2027.
• Ligand raised the low end of 2026 adjusted EPS guidance to $9.00 while maintaining the $9.50 upper end, reaffirmed royalty revenue guidance of $225 million-$250 million, and retains approximately $700 million of deployable capital plus expected operating cash flow exceeding $200 million in 2026.
• Management highlighted a catalyst-rich 18-month period, including up to seven pivotal readouts and potential approvals or label expansions for products such as QTORIN rapamycin, OJEMDA, volixibat, and VABYSMO, while acknowledging the inherent binary risk of clinical development.
• Mirum’s volixibat program in primary sclerosing cholangitis faces a timeline delay after the FDA recommended a Phase III trial; Ligand said the company is pursuing further discussions and now targets a potential submission in the first half of 2027.

Ligand Pharmaceuticals Stock Performance

Shares of NASDAQ LGND traded down $6.99 during trading hours on Friday, hitting $293.15. 313,611 shares of the company’s stock were exchanged, compared to its average volume of 300,344. Ligand Pharmaceuticals has a 1-year low of $137.14 and a 1-year high of $326.63. The stock has a market capitalization of $5.87 billion, a price-to-earnings ratio of 31.35, a PEG ratio of 2.71 and a beta of 1.13. The company’s 50-day moving average price is $285.97 and its 200-day moving average price is $235.30. The company has a debt-to-equity ratio of 1.16, a current ratio of 34.52 and a quick ratio of 20.95.

More Ligand Pharmaceuticals News

Here are the key news stories impacting Ligand Pharmaceuticals this week:

• Positive Sentiment: Ligand reported second-quarter adjusted EPS of $2.37, beating analysts’ $1.95 consensus estimate, while revenue of $63.69 million exceeded expectations of $60.87 million. Revenue increased 33.8% year over year, and EPS rose from $1.60 in the prior-year quarter. Ligand Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The company raised its fiscal 2026 adjusted EPS outlook to $9.00-$9.50, above the $8.13 analyst consensus. The outlook implies continued earnings growth and supports the investment case for Ligand’s royalty-focused business model. Ligand Pharmaceuticals Q2 Adjusted Earnings, Revenue Rise; 2026 Adjusted EPS Outlook Lifted, Revenue Outlook Reaffirmed
• Positive Sentiment: Royal Bank of Canada raised its price target from $340 to $345 and maintained an “outperform” rating. HC Wainwright also lifted its target from $289 to $358 and assigned a “buy” rating, signaling that analysts see further upside. Analyst Price Target Updates
• Neutral Sentiment: Ligand reaffirmed fiscal 2026 revenue guidance of $270 million-$310 million. Although the midpoint is below the $287.5 million consensus estimate, the range remains consistent with the company’s previous outlook and may reflect the timing of royalty and licensing revenue. Ligand Pharmaceuticals 2026 Q2 Results Presentation
• Negative Sentiment: The stock’s decline following the earnings beat suggests investors may have been looking for a larger revenue outlook increase or may be locking in gains after the shares’ strong run. The mixed revenue guidance could be limiting the immediate reaction to the otherwise favorable results. Biopharma Royalty Powerhouse Dips Despite Beat-and-Raise Quarter

Insider Activity

In other Ligand Pharmaceuticals news, Director Jason Haas sold 6,461 shares of the stock in a transaction on Friday, June 12th. The shares were sold at an average price of $255.58, for a total value of $1,651,302.38. Following the completion of the sale, the director directly owned 4,981 shares of the company’s stock, valued at $1,273,043.98. This represents a 56.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director John L. Lamattina sold 4,591 shares of the stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $250.88, for a total transaction of $1,151,790.08. Following the completion of the sale, the director owned 26,969 shares of the company’s stock, valued at approximately $6,765,982.72. The trade was a 14.55% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 35,231 shares of company stock worth $9,199,401. Corporate insiders own 5.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Commonwealth Equity Services LLC bought a new position in shares of Ligand Pharmaceuticals during the 4th quarter worth approximately $209,000. Principal Securities Inc. grew its holdings in Ligand Pharmaceuticals by 237.4% during the 4th quarter. Principal Securities Inc. now owns 1,127 shares of the biotechnology company’s stock worth $213,000 after acquiring an additional 793 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Ligand Pharmaceuticals in the third quarter valued at approximately $210,000. Mackenzie Financial Corp acquired a new stake in shares of Ligand Pharmaceuticals in the 3rd quarter valued at $207,000. Finally, Orion Porfolio Solutions LLC acquired a new stake in Ligand Pharmaceuticals in the third quarter worth about $210,000. Institutional investors own 91.28% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Weiss Ratings downgraded shares of Ligand Pharmaceuticals from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 15th. Bank of America upped their target price on Ligand Pharmaceuticals from $266.00 to $388.00 and gave the company a “buy” rating in a report on Thursday, July 9th. Oppenheimer reaffirmed an “outperform” rating and issued a $326.00 price objective (up from $285.00) on shares of Ligand Pharmaceuticals in a research note on Monday, August 3rd. Stifel Nicolaus lifted their target price on Ligand Pharmaceuticals from $255.00 to $332.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. Finally, HC Wainwright boosted their price target on shares of Ligand Pharmaceuticals from $289.00 to $358.00 and gave the company a “buy” rating in a report on Thursday. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Ligand Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $336.57.

Ligand Pharmaceuticals Company Profile

Ligand Pharmaceuticals, Inc is a biopharmaceutical company that acquires, develops and out-licenses proprietary technologies designed to help pharmaceutical and biotechnology companies discover and develop novel medicines. Operating primarily through its research services and royalty-generating businesses, Ligand focuses on building a diversified portfolio of technology platforms and partnering with industry leaders to advance therapeutic candidates across multiple disease areas.

The company’s product offerings center around several core platforms.